Cargando…

Rosiglitazone decreases postprandial production of acylation stimulating protein in type 2 diabetics

BACKGROUND: We evaluated plasma ASP and its precursor C3 in type 2 diabetic men with/without rosiglitazone (ROSI) treatment compared to healthy non-obese men. We tested (1) whether plasma ASP or C3 are altered postprandially in subcutaneous adipose tissue or forearm muscle effluent assessed by arter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tahiri, Youssef, Karpe, Fredrik, Tan, Garry D, Cianflone, Katherine
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1876462/ https://www.ncbi.nlm.nih.gov/pubmed/17490487 http://dx.doi.org/10.1186/1743-7075-4-11

Ejemplares similares

Plasma Levels of Acylation-Stimulating Protein Are Strongly Predicted by Waist/Hip Ratio and Correlate with Decreased LDL Size in Men
por: Saleh, Jumana, et al.
Publicado: (2013)

Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects
por: Liu, Yan, et al.
Publicado: (2014)

Type 1 diabetes and low carbohydrate diets—Defining the degree of nutritional ketosis
por: Ozoran, Hakan, et al.
Publicado: (2023)

The effects of acylation stimulating protein supplementation VS antibody neutralization on energy expenditure in wildtype mice
por: Paglialunga, Sabina, et al.
Publicado: (2010)

Racial difference in Acylation Stimulating Protein (ASP) correlates to triglyceride in non-obese and obese African American and Caucasian women
por: Scantlebury-Manning, Thea, et al.
Publicado: (2009)

Fasting and postprandial acyl and desacyl ghrelin and the acyl/desacyl ratio in obese patients before and after different types of bariatric surgery
por: Dardzińska, Jolanta A., et al.
Publicado: (2018)

Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes
por: Hiyoshi, Toru, et al.
Publicado: (2019)

Thyroid status influence on adiponectin, acylation stimulating protein (ASP) and complement C3 in hyperthyroid and hypothyroid subjects
por: Yu, Haiying, et al.
Publicado: (2006)

Plasma Gamma-Glutamyltransferase Is Strongly Determined by Acylation Stimulating Protein Levels Independent of Insulin Resistance in Patients with Acute Coronary Syndrome
por: Saleh, Jumana, et al.
Publicado: (2013)

Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone
por: Håkansson, Joakim, et al.
Publicado: (2011)

Recombinant Acylation Stimulating Protein Administration to C3(−/−) Mice Increases Insulin Resistance via Adipocyte Inflammatory Mechanisms
por: Munkonda, Mercedes Nancy, et al.
Publicado: (2012)

Resistin Production from Adipose Tissue Is Decreased in db/db Obese Mice, and Is Reversed by Rosiglitazone
por: Ye, Hongying, et al.
Publicado: (2013)

Effects of Sugar-sweetened Beverages on plasma Acylation Stimulating Protein, Leptin & Adiponectin and Metabolic Parameters
por: Rezvani, Reza, et al.
Publicado: (2013)

Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes
por: Han, Eugene, et al.
Publicado: (2016)

Leukemia and rosiglitazone
por: Yavasoglu, Irfan, et al.
Publicado: (2016)

Acute Effects of Exogenous Hormone Administration on Postprandial Acylation Stimulating Protein Levels in Ovariectomized Rats after a Fat Load
por: Al Riyami, Bashair, et al.
Publicado: (2014)

Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal
Publicado: (2011)

Safety and efficacy of rosiglitazone in the elderly diabetic patient
por: Viljoen, Adie, et al.
Publicado: (2009)

Administration of exogenous acylated ghrelin or rikkunshito, an endogenous ghrelin enhancer, improves the decrease in postprandial gastric motility in an acute restraint stress mouse model
por: Nahata, M, et al.
Publicado: (2014)

Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content
por: Ravikumar, Balasubramanian, et al.
Publicado: (2008)

Postprandial Blood Pressure Decrease in Patients with Type 2 Diabetes and Mild or Severe Cardiac Autonomic Dysfunction
por: Hashizume, Masahiko, et al.
Publicado: (2019)

Acylation stimulating protein reduction precedes insulin sensitization after BPD-DS bariatric surgery in severely obese women
por: Munkonda, M N, et al.
Publicado: (2012)

The Janus face of rosiglitazone
por: Pich, Christine, et al.
Publicado: (2018)

Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?
por: Rahman, Sayeeda, et al.
Publicado: (2009)

Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes
por: Zheng, Jing-Quan, et al.
Publicado: (2012)

Rosiglitazone and Cognitive Stability in Older Individuals With Type 2 Diabetes and Mild Cognitive Impairment
por: Abbatecola, Angela M., et al.
Publicado: (2010)

Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients
por: Tseng, Chin-Hsiao
Publicado: (2019)

Safety and Effectiveness of Rosiglitazone in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease
por: Wang, Chao-Hung, et al.
Publicado: (2006)

Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats
por: Rao, Ravi Prakash, et al.
Publicado: (2011)

Protective effect of rosiglitazone, quercetin, and their combination on fructose-induced metabolic syndrome in rats
por: Abo-youssef, Amira M.
Publicado: (2015)

Transcriptome Alteration in the Diabetic Heart by Rosiglitazone: Implications for Cardiovascular Mortality
por: Wilson, Kitchener D., et al.
Publicado: (2008)

Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial
por: Florez, H, et al.
Publicado: (2015)

Effects of aging and type 2 diabetes on resting and post occlusive hyperemia of the forearm; the impact of rosiglitazone
por: Petrofsky, Jerrold, et al.
Publicado: (2005)

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
por: Komajda, Michel, et al.
Publicado: (2010)

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
por: Sullivan, Sean D, et al.
Publicado: (2009)

Long-Term Effects of Rosiglitazone on the Progressive Decline in Renal Function in Patients With Type 2 Diabetes
por: Kim, Mee Kyoung, et al.
Publicado: (2009)

Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus
por: Atamer, Y., et al.
Publicado: (2013)

Rosiglitazone Increases Cerebral Klotho Expression to Reverse Baroreflex in Type 1-Like Diabetic Rats
por: Chen, Li-Jen, et al.
Publicado: (2014)

Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus
por: Tseng, Chin-Hsiao
Publicado: (2016)

Development of Heart Failure in Medicaid Patients with Type 2 Diabetes Treated with Pioglitazone, Rosiglitazone, or Metformin
por: Breunig, Ian M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4eqoflig2irqam3nlbqa0ulhgn